Clinical trial NCT01275092: Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)
Official title: CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Keywords: robotic-assisted PCI
coronary intervention
CorPath PRECISE
PCI
Lead sponsor: Corindus Inc.
Sponsor class: INDUSTRY
First posted: 2011-01-12
Enrollment: 164
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate the safety and effectiveness of the clinical and technical performance of the CorPath® 200 System in the delivery and manipulation of coronary guidewires and stent/balloon systems for use in percutaneous coronary interventions (PCI).


Eligibility criteria: General Inclusion Criteria:

1. Subject is between 18 and 99 years of age.
2. Subject is an acceptable candidate for PCI.
3. Subject must have clinical evidence of ischemic heart disease or a positive functional study.
4. Female subjects must be of non-child bearing potential, or if able to bear children, have a negative pregnancy test within 7 days prior to the CorPath procedure.
5. The subject or the legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.

Angiographic Inclusion Criteria:

1. Study lesion is a single de novo native coronary artery lesion. This lesion may consist of multiple lesions (with 10mm or less between diseased segments) and must be completely covered by a single stent with at least 2.0mm of normal segments on proximal and distal edges of the lesion.
2. Study reference vessel diameter is between 2.5mm and 4.0mm by visual estimate.
3. Study lesion length is less than or equal to 24.0mm by visual estimate.
4. Study lesion diameter showing stenosis of at least 50% by visual estimate.

General Exclusion Criteria:

1. Subject requires planned PCI or CABG (Coronary Artery Bypass Graft) within 30 days following the CorPath procedure.
2. Evidence of an acute myocardial infarction within 72 hours prior to the intended CorPath procedure.
3. Subject has documented left ventricular ejection fraction \<30%.
4. Subject has undergone PCI within 72 hours prior to the CorPath procedure.
5. Subject has undergone PCI within 30 days prior to the CorPath procedure and experienced a major adverse coronary event (MACE) or a serious adverse event (SAE) as defined in the protocol.
6. Subject has known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, prasugrel, stainless steel, cobalt chromium, or sensitivity to contrast media, including Visipaque™, which cannot be adequately pre-medicated or managed with clinically appropriate substitutes.
7. Subject has a platelet count \<100,000 cells/mm3 or \>700,000 cells/mm3, or a WBC (white blood cell) count of \<3,000 cells/mm3 (e.g. thrombocytopenia, thrombocythemia, neutropenia or leukopenia).
8. Subject has a serum creatinine level of \>2.0 mg/dL or eGFR (estimated Glomerular Filtration Rate) \<30 ml/min as measured within 7 days prior to the procedure.
9. Subject has suffered a stroke within 30 days prior to planned CorPath procedure.
10. Subject has an active peptic ulcer or upper gastrointestinal bleeding within the 6 months prior to planned CorPath procedure.
11. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
12. Subject is currently participating in another investigational drug or drug/device or device trial and has not completed the entire follow up period.
13. Femoral access is not possible.

Angiographic Exclusion Criteria:

1. Target lesion that cannot be fully covered by a single stent.
2. Subject requires treatment of more than one vessel.
3. Any previous stent placement within 5.0 mm (proximal or distal) of the target lesion.
4. The study lesion requires planned treatment with directional coronary atherectomy (DCA), laser, rotational atherectomy or any device except for balloon dilatation prior to stent placement.
5. The study vessel has evidence of intraluminal thrombus.
6. The study vessel has evidence of moderate to severe tortuosity (\>90°) proximal to the target lesion.
7. The study lesion has any of the following characteristics:

   * Total occlusion.
   * Ostial location.
   * Is within 2.0 mm of a side branch measuring \>2.0 mm in diameter.
   * Located at \< 45° bend in the vessel.
   * Moderately to severely calcified.
   * Moderate to severe calcification in the vessel proximal to the target lesion.
   * Located in a native vessel distal to an anastomosis, with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass, and is approached through the bypass graft.
8. Unprotected left main coronary artery disease defined as an obstruction greater than 50% diameter stenosis in the left main coronary artery.

Primary outcomes:
measure: Percentage of Participants With Clinical Procedural Success
timeFrame: 48-hrs or hospital discharge, whichever occurs first
measure: Percentage of Patients With Device Technical Success
timeFrame: 1 day
Secondary outcomes:
measure: The Ratio Between the Radiation Exposure of the Primary Operator and the Radiation Exposure at the Table
timeFrame: 1 day
Other outcomes:
Locations:
city: Washington
country: United States
facility: Washington Hospital Center
state: District of Columbia
city: Gainesville
country: United States
facility: Northeast Georgia Heart Center
state: Georgia
city: Boston
country: United States
facility: St. Elizabeth's Medical Center
state: Massachusetts
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Syracuse
country: United States
facility: Saint Joseph's Hospital
state: New York
city: Kingsport
country: United States
facility: Wellmont CVA Heart Institute
state: Tennessee
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
city: Seattle
country: United States
facility: Swedish Medical Center
state: Washington
city: Medellin
country: Colombia
facility: CORBIC
Study officials:
affiliation: Corindus Inc.
name: Michail Pankratov, MD/PhD
role: STUDY_DIRECTOR
References:
citation: Weisz G, Metzger DC, Caputo RP, Delgado JA, Marshall JJ, Vetrovec GW, Reisman M, Waksman R, Granada JF, Novack V, Moses JW, Carrozza JP. Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study. J Am Coll Cardiol. 2013 Apr 16;61(15):1596-600. doi: 10.1016/j.jacc.2012.12.045.